Comparative Pharmacology
Head-to-head clinical analysis: CEFOTAN versus CEFTAROLINE FOSAMIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTAN versus CEFTAROLINE FOSAMIL.
CEFOTAN vs CEFTAROLINE FOSAMIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotetan is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, and activating autolytic enzymes.
Ceftaroline fosamil is a prodrug that is converted to the active metabolite ceftaroline. Ceftaroline inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), including PBP2a in MRSA and PBP2x in Streptococcus pneumoniae, thereby preventing cross-linking of peptidoglycan.
1-2 g IV/IM every 12 hours for 5-10 days; up to 6 g/day for severe infections.
600 mg IV every 12 hours infused over 1 hour
None Documented
None Documented
Terminal elimination half-life: 4.5 hours (intravenous). In patients with renal impairment (CrCl <30 mL/min), half-life extends to approximately 20–30 hours, requiring dose adjustment.
Terminal elimination half-life is approximately 2.6 hours in patients with normal renal function. This supports twice-daily dosing in most infections.
Primarily renal (unchanged); ~88% excreted in urine within 24 hours. Biliary/fecal elimination is negligible (<1% as metabolites).
Renal excretion of unchanged ceftaroline accounts for approximately 88% of the administered dose. Biliary/fecal elimination is minimal (<6%).
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic